Literature DB >> 16171993

3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.

Jotham W Coe1, Paige R Brooks, Michael C Wirtz, Crystal G Bashore, Krista E Bianco, Michael G Vetelino, Eric P Arnold, Lorraine A Lebel, Carol B Fox, F David Tingley, David W Schulz, Thomas I Davis, Steven B Sands, Robert S Mansbach, Hans Rollema, Brian T O'Neill.   

Abstract

3,5-Bicyclic aryl piperidines are a new class of high-affinity alpha4beta2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the alpha4beta2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16171993     DOI: 10.1016/j.bmcl.2005.08.035

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

2.  Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats.

Authors:  Steven T Pittenger; Shinnyi Chou; Scott T Barrett; Isabella Catalano; Maxwell Lydiatt; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2017-07-13       Impact factor: 3.533

3.  Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.

Authors:  Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

Review 4.  Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.

Authors:  S Chatterjee; S E Bartlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

5.  ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation.

Authors:  L Cinnamon Bidwell; Hollis C Karoly; Kent E Hutchison; Angela D Bryan
Journal:  Drug Alcohol Depend       Date:  2017-07-18       Impact factor: 4.492

6.  Cycloadditions of Oxacyclic Allenes and a Catalytic Asymmetric Entryway to Enantioenriched Cyclic Allenes.

Authors:  Michael M Yamano; Rachel R Knapp; Aurapat Ngamnithiporn; Melissa Ramirez; Kendall N Houk; Brian M Stoltz; Neil K Garg
Journal:  Angew Chem Int Ed Engl       Date:  2019-03-20       Impact factor: 15.336

Review 7.  Varenicline: a review of its use as an aid to smoking cessation therapy.

Authors:  Gillian M Keating; M Asif A Siddiqui
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

8.  Safety Assessment of Benzyne Generation from a Silyl Triflate Precursor.

Authors:  Andrew V Kelleghan; Carl A Busacca; Max Sarvestani; Ivan Volchkov; Jose M Medina; Neil K Garg
Journal:  Org Lett       Date:  2020-02-04       Impact factor: 6.005

9.  Concise Approach to Cyclohexyne and 1,2-Cyclohexadiene Precursors.

Authors:  Jason V Chari; Francesca M Ippoliti; Neil K Garg
Journal:  J Org Chem       Date:  2019-03-06       Impact factor: 4.354

10.  The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats.

Authors:  Steven T Pittenger; Lindsey C Zeplin; Linda P Dwoskin; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2015-09-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.